Faculty of Health and Medicine, Lancaster University, Lancaster, UK.
Department of Rheumatology, University Hospitals of Morecambe Bay NHS Foundation Trust, Royal Lancaster Infirmary, Lancaster, UK.
Rheumatology (Oxford). 2018 Jun 1;57(6):951-958. doi: 10.1093/rheumatology/kex343.
Gout is the most common cause of inflammatory arthritis worldwide, and reports show that despite availability of therapies, management is still suboptimal. The new EULAR 2016 recommendations for the treatment of gout highlight the huge development in gout therapies, and the number of drugs being trialled only continues to increase. A clinical review of the evidence that underlies the recommendations from EULAR can reveal possible gaps in the literature and avenues for future research into gout therapies.
痛风是全球范围内最常见的炎症性关节炎，有报道显示，尽管有治疗方法，但管理仍不尽如人意。新的 2016 年 EULAR 痛风治疗建议突出了痛风治疗方面的巨大进展，而且正在试验的药物数量还在不断增加。对 EULAR 建议所依据的证据进行临床审查，可以发现文献中的可能空白，并为痛风治疗的未来研究提供方向。
